NR1H4 and metabolic dysfunction-associated steatotic liver disease: CAG can reportedly stimulate the transcriptional activity of farnesoid X receptor (FXR), a potential drug target for the treatment of non-alcoholic fatty liver disease (Chiang and Ferrell, 2020; Gu et al., 2017).